Diagonal Bio AB (publ) (DIABIO.ST)
SEK 0.01
(0.0%)
SEK 0.01
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -2.97 Million SEK | 78.12% |
| 2022 | -13.58 Million SEK | 34.58% |
| 2021 | -20.76 Million SEK | -466.14% |
| 2020 | -3.66 Million SEK | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q3 | -1.73 Million SEK | 58.39% |
| 2024 Q1 | -1.85 Million SEK | 37.55% |
| 2024 Q2 | -4.15 Million SEK | -124.03% |
| 2023 FY | -2.97 Million SEK | 78.12% |
| 2023 Q4 | -2.97 Million SEK | 36.99% |
| 2023 Q3 | -4.71 Million SEK | 14.75% |
| 2023 Q2 | -5.53 Million SEK | 43.18% |
| 2023 Q1 | -9.73 Million SEK | 28.33% |
| 2022 FY | -13.58 Million SEK | 34.58% |
| 2022 Q4 | -13.58 Million SEK | -26.16% |
| 2022 Q3 | -10.76 Million SEK | 34.48% |
| 2022 Q2 | -16.43 Million SEK | 2.87% |
| 2022 Q1 | -16.92 Million SEK | 18.52% |
| 2021 Q1 | -349 Thousand SEK | 90.49% |
| 2021 FY | -20.76 Million SEK | -466.14% |
| 2021 Q3 | -24.89 Million SEK | -459.2% |
| 2021 Q2 | -4.45 Million SEK | -1175.36% |
| 2021 Q4 | -20.76 Million SEK | 16.57% |
| 2020 Q4 | -3.66 Million SEK | 0.0% |
| 2020 FY | -3.66 Million SEK | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Calliditas Therapeutics AB (publ) | 5.4 Million SEK | 155.037% |
| AcouSort AB (publ) | -23.98 Million SEK | 87.609% |
| Active Biotech AB (publ) | -33.2 Million SEK | 91.048% |
| Alzinova AB (publ) | -21.22 Million SEK | 85.998% |
| Amniotics AB (publ) | -5.63 Million SEK | 47.23% |
| Asarina Pharma AB (publ) | -2.16 Million SEK | -37.529% |
| BioArctic AB (publ) | -606.58 Million SEK | 99.51% |
| Camurus AB (publ) | -1.16 Billion SEK | 99.745% |
| Cantargia AB (publ) | -139.74 Million SEK | 97.873% |
| Scandinavian ChemoTech AB (publ) | -923 Thousand SEK | -221.993% |
| Elicera Therapeutics AB (publ) | -29.38 Million SEK | 89.885% |
| Genovis AB (publ.) | -43.94 Million SEK | 93.236% |
| Guard Therapeutics International AB (publ) | -83.74 Million SEK | 96.451% |
| Mendus AB (publ) | -96.29 Million SEK | 96.914% |
| Kancera AB (publ) | -45.69 Million SEK | 93.496% |
| Karolinska Development AB (publ) | -82.2 Million SEK | 96.385% |
| LIDDS AB (publ) | -13.51 Million SEK | 78.005% |
| Lipum AB (publ) | -8.46 Million SEK | 64.891% |
| Lipigon Pharmaceuticals AB (publ) | -31.92 Million SEK | 90.691% |
| Magle Chemoswed Holding AB (publ) | 53.22 Million SEK | 105.584% |
| Modus Therapeutics Holding AB (publ) | -19.06 Million SEK | 84.407% |
| NextCell Pharma AB | -46.79 Million SEK | 93.648% |
| OncoZenge AB (publ) | -12.62 Million SEK | 76.463% |
| Saniona AB (publ) | 40.44 Million SEK | 107.348% |
| Simris Alg AB (publ) | 85.07 Million SEK | 103.493% |
| Vicore Pharma Holding AB (publ) | -333.62 Million SEK | 99.109% |
| Xbrane Biopharma AB (publ) | 166.07 Million SEK | 101.79% |
| Xintela AB (publ) | -7.8 Million SEK | 61.941% |
| Ziccum AB (publ) | -2.13 Million SEK | -39.073% |
| Isofol Medical AB (publ) | -138.14 Million SEK | 97.849% |
| Xspray Pharma AB (publ) | -129.49 Million SEK | 97.705% |
| CombiGene AB (publ) | -101.44 Million SEK | 97.07% |
| Diamyd Medical AB (publ) | -82.08 Million SEK | 96.379% |
| Intervacc AB (publ) | -88.16 Million SEK | 96.629% |
| Alligator Bioscience AB (publ) | -50.02 Million SEK | 94.058% |
| Sprint Bioscience AB (publ) | -49.93 Million SEK | 94.048% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 20.51 Million SEK | 114.49% |
| Corline Biomedical AB | -17.01 Million SEK | 82.53% |
| IRLAB Therapeutics AB (publ) | -83.74 Million SEK | 96.451% |
| Bio-Works Technologies AB (publ) | -39.38 Million SEK | 92.453% |
| Aptahem AB (publ) | 2.9 Million SEK | 202.178% |
| Infant Bacterial Therapeutics AB (publ) | -329.06 Million SEK | 99.097% |
| Fluicell AB (publ) | -2.76 Million SEK | -7.564% |
| Biovica International AB (publ) | -58.73 Million SEK | 94.94% |
| Spago Nanomedical AB (publ) | -45.21 Million SEK | 93.427% |
| Abliva AB (publ) | -57.24 Million SEK | 94.808% |
| Egetis Therapeutics AB (publ) | -194.7 Million SEK | 98.474% |
| 2cureX AB (publ) | -13.4 Million SEK | 77.826% |
| I-Tech AB | -83.26 Million SEK | 96.431% |
| Hansa Biopharma AB (publ) | 134.7 Million SEK | 102.206% |
| Cyxone AB (publ) | -16.67 Million SEK | 82.172% |
| ExpreS2ion Biotech Holding AB (publ) | -55.88 Million SEK | 94.682% |
| Biosergen AB | -1.88 Million SEK | -57.833% |
| Nanologica AB (publ) | -9.38 Million SEK | 68.343% |
| SynAct Pharma AB | -61.75 Million SEK | 95.188% |
| Annexin Pharmaceuticals AB (publ) | -21.41 Million SEK | 86.122% |
| BioInvent International AB (publ) | -236.3 Million SEK | 98.742% |
| Stayble Therapeutics AB (publ) | -13.22 Million SEK | 77.535% |
| Oncopeptides AB (publ) | -66.92 Million SEK | 95.559% |
| Pila Pharma AB (publ) | -5.18 Million SEK | 42.636% |
| Ascelia Pharma AB (publ) | -20.79 Million SEK | 85.707% |